Skip to main content
. 2012 Dec 28;5(3):983–991. doi: 10.3892/ol.2012.1093

Table II.

Study characteristics for patients receiving chemotherapy for neo-adjuvant cancer.

Authors (Ref.) Sample Mean age (year) Clinical stage Mean tumor size (cm) Drugs and dose Surgery rate Outcomes Toxicities of grade III–IV
Sirohi, et al 1 (9) TN: 17
Non-TN: 77
TN: 50
Non-TN: 46
T3–T4
Nx; M0
NR 5 FU: 200 mg/m2
DDP: 60 mg/m2
EPI: 60 mg/m2
day 1 for 21 days*6
6 (35%)
P=0.005
54 (70%)
P=0.007
cCR, PR, pD NR
Chang, et al(10) TN: 11
Non-TN: 62
49.6 T2–T4
Nx; M0
7.75 DOC: 75 mg/m2
Carboplatin: AUC=6
day 1 for 21 days*4
71 pCR, cCR,
2-year OS,
5-year OS
Neutropenia, leukopenia, lymphopenia, febrileneutropenia
Chen, et al(11) TN: 24
Non-TN: 84
51 II–IIIC NR Carboplatin: AUC=2
Taxol: 180 mg/m2
days 1+8+15 for 28 days*4
108 pCR Neutropenia, thrombocytopenia, anemia, skin toxicity
Silver, et al(6) TN: 28 29–69 II–III 3.7 (2.0–7.0) DDP: 75 mg/m2
day 1 for 21 days*4
28 pCR: 6 (21%)
cCR+PR:
18 (64%)
PD: 4 (14%)
Tinnitus, neutropenia, hyperkalemia, elevation of ALT/AST, nausea, myalgia, skin toxicity

TN, triple-negative breast cancer; Doc, docetaxel; DDP, cisplatin; cCR, clinical complete response; pCR, pathological complete response; PD, progressive disease; OS, overall survival; PFS, progression - free survival; TTP, time to progression; Nx, status of lymph node metastasis is unclear; NR, not reported in the text.